NEW YORK, May 22, 2026, 19:07 (EDT)
Sera Prognostics Inc. ended Friday up 15% at $2.07. The Nasdaq diagnostics stock, which usually sees thin action, saw 531,892 shares change hands—21 times what traded Thursday. SERA opened at $1.69 and touched $2.23 before settling.
Timing is a factor. Sera’s investor-news page listed the May 6 first-quarter update as its most recent, and the filings page also showed May 6 as the latest for both its 8-K and 10-Q. There was no new disclosure from the company to explain Friday’s move.
Wall Street edged up into the Memorial Day weekend, though gains were mixed. The Nasdaq Composite rose 0.2%, but the SPDR S&P Biotech ETF dropped 0.84%, showing less risk appetite in smaller biotech names. The broader market gave a lift that only did so much.
Sera’s story is still focused on commercialization instead of sales right now. The company posted first-quarter revenue of $14,000, falling from $38,000 last year. Net loss hit $8.4 million. Cash, cash equivalents, and available-for-sale securities totaled about $86.8 million as of March 31.
Sera CEO Zhenya Lindgardt said the company used the quarter to “build awareness with clinicians” as it moves from clinical to commercial activity. Sera said it started a third partnership and is talking to 13 payers in 15 states. Getting reimbursement from insurers or government health plans is key to making money from its tests. PR Newswire
Sera CFO Austin Aerts told investors 2026 revenue could still be “modest and uneven,” citing the pace of reimbursement, awareness, and advocacy efforts. He also said the company expects about $10 million in yearly expense cuts, with most of that impact hitting from 2027. Investing
Sera’s PreTRM test checks protein levels in a mother’s blood at 18 to 20 weeks to predict the odds of early birth in single pregnancies. It’s a risk-screening tool, not meant for treatment. The key issue is if doctors will use it enough and if insurers will pay for it.
Other stocks in the group traded mixed. Natera ended off 0.25%, Myriad Genetics lost 2.3%, and Quest Diagnostics added 0.72%. The move in Sera looked isolated, not tied to a sector-wide move.
But the risk is still clear. Sera’s latest 10-Q says the company hasn’t posted much commercial revenue, is likely to keep losing money, and needs PreTRM adoption to succeed. Sera also flagged that its stock could swing a lot, pointing to thin trading, plus reimbursement and adoption risks.
U.S. equity markets are closed Monday, May 25, for Memorial Day, according to the Nasdaq calendar. Trading picks up again Tuesday. For Sera, what matters now isn’t another jump in price, but seeing if payer discussions actually lead to covered tests and orders.
